Speaker illustration

Professor John Chapman

Sorbonne University, Paris (France)

Member of:

European Society of Cardiology

Dyslipidaemia management: a moving target!

Event: ESC Preventive Cardiology 2022

Topic: Lipids

Session type: Symposium

Thumbnail

Add on to take back control: Combining lipid lowering therapies for the management of high risk patients

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Drug therapy

Session type: Industry Q&A session

Thumbnail

Beyond statins - Evolving concepts for the management of dyslipidaemia

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

PCSK9i, changing practice in cardiology: the emerging story

Event: ESC CONGRESS 2019

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Meet the Trialists - HPS3/TIMI55-REVEAL

Event: ESC CONGRESS 2017

Topic: Lipids (Epidemiology and Prevention)

Session type: Meet the Trialists

Thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in CVD prevention

Event: ESC CONGRESS 2017

Topic: Atherosclerosis

Session type: Satellite Symposium

Thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: the next chapter in cardiovascular disease prevention

Event: ESC CONGRESS 2017

Topic: Atherosclerosis

Session type: Satellite Symposium

Thumbnail

Triglycerides and cardiovascular risk: the importance of treating hypertriglyceridaemia

Event: ESC CONGRESS 2014

Topic: Primary cardiovascular prevention: interventions and outcomes

Session type: EBAC Accredited Educational Programme

Thumbnail

This platform is supported by

logo Novo Nordisk